Please assess the completion status of the following clinical trial:

Trial Title: DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
1. Male and female adult patients (age ≥ 20 years old)~2. Patients diagnosed with unresectable HCC \[Child Pugh class A and major vascular invasion, extrahapatic metastasis, or progression after transarterial chemoembolization more than 2 times\]~3. Presence of mRECIST target lesion within liver \[lesion which can be classified as a RECIST measurable lesion (can be measured ≥ 1 cm in at least one dimension), lesion suitable for repeated measure, lesion showing intraluminal arterial enhancement on contrast-enhanced CT or MRI\]~4. Patients planned to be treated with sorafenib~5. Patient with liver CT performed or planned to be performed within 4 weeks before initiation of sorafenib treatment~6. Patient with a life expectancy of 12 weeks or more~7. No previous treatment with sorafenib~8. Female patients who are surgically sterilized, or post-menopausal (minimum 12 months of amenorrhea) or who have a documented negative urine hCG test at screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gadoterate meglumine (Type: EXPERIMENTAL): there is one single arm of patients (no comparative arm)

Based on this trial design, predict the completion outcome and termination type (if applicable).